Vergoeding 2016-2020 voor ATC-subgroep N03AX : Overige anti-epileptica
- Raming voor de totale Zvw-populatie
| 2016 | 2017 | 2018 | 2019 | 2020 | |
|---|---|---|---|---|---|
| N03AX03 Sultiam (Ospolot ®) | 155 | . | . | . | . |
| N03AX09 Lamotrigine (Lamictal ®) | 2.558.600 | 2.435.300 | 2.692.800 | 2.751.300 | 3.000.200 |
| N03AX10 Felbamaat (Taloxa ®) | 128.000 | 132.320 | 118.920 | 118.160 | 121.680 |
| N03AX11 Topiramaat (Topamax ®) | 972.640 | 905.010 | 1.107.300 | 1.296.900 | 1.415.000 |
| N03AX12 Gabapentine (Neurontin ®) | 1.478.400 | 1.388.300 | 1.585.100 | 1.871.100 | 1.910.700 |
| N03AX14 Levetiracetam (Keppra ®) | 5.754.900 | 4.735.900 | 5.209.200 | 5.179.600 | 6.713.500 |
| N03AX15 Zonisamide (Zonegran ®) | 506.320 | 438.840 | 383.930 | 367.280 | 363.890 |
| N03AX16 Pregabaline (Lyrica ®) | 31.931.900 | 23.870.500 | 9.329.500 | 8.458.500 | 9.004.900 |
| N03AX17 Stiripentol (Diacomit ®) | 397.340 | 450.470 | 451.630 | 421.600 | 389.410 |
| N03AX18 Lacosamide (Vimpat ®) | 3.006.800 | 3.569.500 | 4.198.300 | 4.913.800 | 5.366.000 |
| N03AX21 Retigabine | 21.523 | 1.488 | . | . | . |
| N03AX22 Perampanel (Fycompa ®) | 527.780 | 547.980 | 593.370 | 674.690 | 733.220 |
| N03AX23 Brivaracetam (Briviact ®) | 48.261 | 436.800 | 950.940 | 1.655.400 | 2.148.300 |
| Totaal | 47.332.619 | 38.912.408 | 26.620.990 | 27.708.330 | 31.166.800 |